17.07.2014 • News

Luciano Rossetti Moves from Merck to Merck

Merck Serono, the biopharmaceutical division of Germany's Merck KGaA has appointed Luciano Rossetti as executive vice president and global head of research & development with effect from July 2.

Rossetti most recently was Senior Vice President Late Stage Development at US pharmaceutical producer Merck Sharp & Dohme, where he was responsible for the entire clinical development from Phase II to Phase V across all therapeutic areas.

The new R&D chief will be based in Billerica, outside Boston, Massachusetts, in the US, one of Merck Serono's four global R&D hubs, and will share his time between Merck's headquarters in Darmstadt, Germany, and Billerica.

Interview

The UK Chemical Supply Chain
Trade and Competitiveness

The UK Chemical Supply Chain

The CBA, led by CEO Tim Doggett, is steering the UK chemical supply chain through trade uncertainty, sustainability pressures and logistics challenges, as he explains in this interview with CHEManager.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.